Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
DIABETOLOGY / BASIC RESEARCH
lncRNA SNHG6 improves placental villous cell function
in an in vitro model of gestational diabetes mellitus
1
Department of Gynecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2
Maternity Department, Lianyungang Maternal and Child Health Hospital, Lianyungang, Jiangsu, China
3
Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Jiangsu Key Laboratory of Clinical Immunology, Soochow University, Jiangsu Key Laboratory of Gastrointestinal tumor Immunology, Suzhou, Jiangsu, China
Submission date: 2020-07-05
Final revision date: 2020-09-04
Acceptance date: 2020-09-05
Online publication date: 2020-11-06
Publication date: 2026-09-15
Corresponding author
Fei Xia
Department of Gynecology and Obstetrics The First Affiliated Hospital of Soochow University Suzhou, Jiangsu 215006 China
Department of Gynecology and Obstetrics The First Affiliated Hospital of Soochow University Suzhou, Jiangsu 215006 China
Arch Med Sci 2026;22(4):2307-2320
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The purpose of this research was to investigate whether lncRNA SNHG6 has an effect on the pathogenesis of gestational diabetes mellitus (GDM).
Material and methods:
Placental tissue was collected from patients with GDM and from pregnant women without GDM. Expression of lncRNA SNHG6 and EZH2 in the placental tissue was detected by qRT-PCR, immunohistochemistry (IHC), and western blotting. An in vitro cell model for GDM using high-dose glucose was employed to measure relative expression of mRNA and proteins by RT-qPCR and WB assay, and cell viability, apoptosis rate, invasion cell number, and wound healing rate by CCK-8, flow cytometry, transwell assay, and wound healing assay, respectively. Correlation between miRNA-26a-5p and EZH2 was investigated with a dual-luciferase reporter assay.
Results:
Compared with the control placenta, lncRNA SNHG6 and EZH2 mRNA expression levels were significantly depressed and EZH2 protein expression was significantly downregulated in GDM placenta tissues (p < 0.001, respectively). In the in vitro cell model, lncRNA SNHG6 overexpression significantly improved high-dose glucose-induced HTR-8/SVneo cell function losses, including proliferation, migration, and invasion, by significantly depressing miRNA-26a-5p via regulation of EZH2 expression. The dual-luciferase reporter assay revealed that miRNA-26a-5p could target to EZH2 in HTR-8/SVneo cells.
Conclusions:
Expression of lncRNA SNHG6 in the placenta of patients with GDM is abnormally decreased. Overexpression of lncRNA SNHG6 improved HTR-8/SVneo cell function via regulation of the miRNA-26a-5p/EZH2-H3K27me3 pathway in an in vitro GDM model.
The purpose of this research was to investigate whether lncRNA SNHG6 has an effect on the pathogenesis of gestational diabetes mellitus (GDM).
Material and methods:
Placental tissue was collected from patients with GDM and from pregnant women without GDM. Expression of lncRNA SNHG6 and EZH2 in the placental tissue was detected by qRT-PCR, immunohistochemistry (IHC), and western blotting. An in vitro cell model for GDM using high-dose glucose was employed to measure relative expression of mRNA and proteins by RT-qPCR and WB assay, and cell viability, apoptosis rate, invasion cell number, and wound healing rate by CCK-8, flow cytometry, transwell assay, and wound healing assay, respectively. Correlation between miRNA-26a-5p and EZH2 was investigated with a dual-luciferase reporter assay.
Results:
Compared with the control placenta, lncRNA SNHG6 and EZH2 mRNA expression levels were significantly depressed and EZH2 protein expression was significantly downregulated in GDM placenta tissues (p < 0.001, respectively). In the in vitro cell model, lncRNA SNHG6 overexpression significantly improved high-dose glucose-induced HTR-8/SVneo cell function losses, including proliferation, migration, and invasion, by significantly depressing miRNA-26a-5p via regulation of EZH2 expression. The dual-luciferase reporter assay revealed that miRNA-26a-5p could target to EZH2 in HTR-8/SVneo cells.
Conclusions:
Expression of lncRNA SNHG6 in the placenta of patients with GDM is abnormally decreased. Overexpression of lncRNA SNHG6 improved HTR-8/SVneo cell function via regulation of the miRNA-26a-5p/EZH2-H3K27me3 pathway in an in vitro GDM model.
REFERENCES (22)
1.
Hanson MA, Bardsley A, De-Regil LM, et al. The International Federation of Gynecology and Obstetrics (FIGO) Recommendations on adolescent, preconception, and maternal nutrition: “think nutrition first”. Int J Gynaecol Obstet 2015; 131 Suppl 4: S213-53.
2.
Abouzeid M, Versace VL, Janus ED, et al. Socio-cultural disparities in GDM burden differ by maternal age at first delivery. PLoS One 2015; 10: e0117085.
3.
Assaf-Balut C, García de la Torre N, Durán A, et al. A Mediterranean diet with additional extra virgin olive oil and pistachios reduces the incidence of gestational diabetes mellitus (GDM): a randomized controlled trial: The St. Carlos GDM prevention study. PLoS One 2017; 12: e0185873.
4.
Lu D, Yang M, Yao Y, Xie Y. A clinical research study on the respective relationships between visfatin and human fetuin A and pregnancy outcomes in gestational diabetes mellitus. Taiwan J Obstet Gynecol 2019; 58: 808-13.
5.
Hepp P, Hutter S, Knabl J, et al. Histone H3 Lysine 9 acetylation is downregulated in gdm placentas and calcitriol supplementation enhanced this effect. Int J Mol Sci 2018; 19: E4061.
6.
Moen GH, Sommer C, Prasad RB, et al. Epigenetic modifications and gestational diabetes: a systematic reviewer of published literature. Eur J Endocrinol 2017; 176: R247-67.
7.
Szemraj-Rogucka ZM, Szemraj J, Masiarek K, Majos A. Circulating microRNAs as biomarkers for myocardial fibrosis in patients with left ventricular non-compaction cardiomyopathy. Arch Med Sci 2019; 15: 376-84.
8.
Abdelsalam L, Ibrahim AA, Shalaby A, et al. Expression of miRNAs-122, -192 and -499 in end stage renal disease associated with acute myocardial infarction. Arch Med Sci 2019; 15: 1247-53.
9.
Ding Y, Wang X, Pan J, et al. Aberrant expression of long non-coding RNAs (lncRNAs) is involved in brain glioma development. Arch Med Sci 2019; 16: 177-88.
10.
Xu M, Chen X, Lin K, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. J Hematol Oncol 2019; 12: 3.
11.
Li Y, Li D, Zhao M, et al. Long noncoding RNA SNHG6 regulates p21 expression via activation of the JNK pathway and regulation of EZH2 in gastric cancer cells. Life Sci 2018; 208: 295-304.
12.
Zhang M, Duan W, Sun W. LncRNA SNHG6 promotes the migration, invasion, and epithelial-mesenchymal transition of colorectal cancer cells by miR-26a/EZH2 axis. Onco Targets Ther 2019; 12: 3349-60.
13.
Ding GL, Wang FF, Shu J, et al. Transgenerational glucose intolerance with Igf2/H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia. Diabetes 2012; 61: 1133-42.
14.
Hamlett WC. Ultrastructure of the maternal-fetal interface of the yolk sac placenta in sharks. Ital J Anat Embryol 2005; 110 (2 Suppl 1): 175-81.
15.
Zhang Y, Wu H, Wang F, Ye M, Zhu H, Bu S. Long non-coding RNA MALAT1 expression in patients with gestational diabetes mellitus. Int J Gynaecol Obstet 2018; 140: 164-9.
16.
Shi Z, Zhao C, Long W, Ding H, Shen R. Microarray expression profile analysis of long non-coding RNAs in umbilical cord plasma reveals their potential role in gestational diabetes-induced macrosomia. Cell Physiol Biochem 2015; 36: 542-54.
17.
Vienberg S, Geiger J, Madsen S, Dalgaard LT. MicroRNAs in metabolism. Acta Physiol 2017; 219: 346-61.
18.
Deiuliis JA. MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes 2016; 40: 88-101.
19.
Zhu Y, Tian F, Li H, Zhou Y, Lu J, Ge Q. Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. Int J Gynaecol Obstet 2015; 130: 49-53.
20.
Aires MB, Dos Santos AC. Effects of maternal diabetes on trophoblast cells. World J Diabetes 2015; 6: 338-44.
21.
Vella S, Pomella S, Leoncini PP, et al. MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma. Clin Epigenetics 2015; 7: 82.
22.
Siddiqi FS, Majumder S, Thai K, et al. The histone methyltransferase enzyme enhancer of zeste homolog 2 protects against podocyte oxidative stress and renal injury in diabetes. J Am Soc Nephrol 2016; 27: 2021-34.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
